218 related articles for article (PubMed ID: 10630825)
1. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
Burgess DS; Hastings RW; Horan JL
Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
[TBL] [Abstract][Full Text] [Related]
2. Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.
Fuchs PC; Barry AL; Brown SD
J Clin Microbiol; 2001 Jan; 39(1):43-6. PubMed ID: 11136745
[TBL] [Abstract][Full Text] [Related]
3. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
[TBL] [Abstract][Full Text] [Related]
4. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.
De Vecchi E; Nicola L; Larosa M; Drago L
BMC Microbiol; 2008 Jan; 8():23. PubMed ID: 18230154
[TBL] [Abstract][Full Text] [Related]
6. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.
Bogdanovich T; Bozdogan B; Appelbaum PC
Antimicrob Agents Chemother; 2006 Mar; 50(3):893-8. PubMed ID: 16495248
[TBL] [Abstract][Full Text] [Related]
7. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
Dorfman MS; Wagner RS; Jamison T; Bell B; Stroman DW
Adv Ther; 2008 Mar; 25(3):208-17. PubMed ID: 18369536
[TBL] [Abstract][Full Text] [Related]
8. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Jones RN; Doern GV; Gerlach EH; Hindler J; Erwin ME
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):243-9. PubMed ID: 7924221
[TBL] [Abstract][Full Text] [Related]
9. Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
Drago L; De Vecchi E; Nicola L; Legnani D; Gismondo MR
APMIS; 2005 Oct; 113(10):655-63. PubMed ID: 16309423
[TBL] [Abstract][Full Text] [Related]
10. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V; Thorburn CE; Knott SJ; Woodnutt G
Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
[TBL] [Abstract][Full Text] [Related]
11. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.
Nilius AM; Beyer JM; Flamm RK; Tanaka SK
J Clin Microbiol; 1997 Jun; 35(6):1311-5. PubMed ID: 9163435
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
Okubo T; Iyobe S; Fujiki Y; Sagai H
Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.
Walker KJ; Larsson AJ; Zabinski RA; Rotschafer JC
Antimicrob Agents Chemother; 1994 Sep; 38(9):2003-7. PubMed ID: 7811010
[TBL] [Abstract][Full Text] [Related]
14. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
[TBL] [Abstract][Full Text] [Related]
15. Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.
Hogan PA; Sheehan DJ
Antimicrob Agents Chemother; 1998 Dec; 42(12):3313-4. PubMed ID: 9835536
[TBL] [Abstract][Full Text] [Related]
16. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
17. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
[TBL] [Abstract][Full Text] [Related]
18. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
Credito KL; Lin G; Pankuch GA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Jan; 45(1):67-72. PubMed ID: 11120946
[TBL] [Abstract][Full Text] [Related]
20. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
Carbon C; Poole MD
J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
